[go: up one dir, main page]

EA201691502A1 - Мутантные стафилококковые антигены - Google Patents

Мутантные стафилококковые антигены

Info

Publication number
EA201691502A1
EA201691502A1 EA201691502A EA201691502A EA201691502A1 EA 201691502 A1 EA201691502 A1 EA 201691502A1 EA 201691502 A EA201691502 A EA 201691502A EA 201691502 A EA201691502 A EA 201691502A EA 201691502 A1 EA201691502 A1 EA 201691502A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mutant
staphylcoccic
antigens
mutant spa
fhud2
Prior art date
Application number
EA201691502A
Other languages
English (en)
Other versions
EA037818B1 (ru
Inventor
Фабио Баньоли
Луиджи Фьяски
Мария Скарселли
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201691502A1 publication Critical patent/EA201691502A1/ru
Publication of EA037818B1 publication Critical patent/EA037818B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Предложен мутантный SpA со сниженной аффинностью к Fcγ-части человеческого IgG. Иммунизация с использованием EsxA, EsxB, FhuD2, Sta011, Hla и указанного мутантного SpA обеспечивает поразительные результаты в модели абсцесса почки, вызываемого инфекцией S.
EA201691502A 2014-03-26 2015-03-24 Мутантные стафилококковые антигены EA037818B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14161861 2014-03-26
EP14192913 2014-11-12
PCT/EP2015/056175 WO2015144653A1 (en) 2014-03-26 2015-03-24 Mutant staphylococcal antigens

Publications (2)

Publication Number Publication Date
EA201691502A1 true EA201691502A1 (ru) 2017-04-28
EA037818B1 EA037818B1 (ru) 2021-05-25

Family

ID=52706188

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691502A EA037818B1 (ru) 2014-03-26 2015-03-24 Мутантные стафилококковые антигены

Country Status (25)

Country Link
US (1) US10328140B2 (ru)
EP (2) EP3639850A1 (ru)
JP (2) JP6894237B2 (ru)
KR (3) KR102027429B1 (ru)
CN (2) CN106103469B (ru)
AU (1) AU2015238512B2 (ru)
BE (2) BE1022744B1 (ru)
CA (1) CA2942450A1 (ru)
CY (1) CY1122537T1 (ru)
DK (1) DK3122378T3 (ru)
EA (1) EA037818B1 (ru)
ES (1) ES2769647T3 (ru)
HR (1) HRP20200217T1 (ru)
HU (1) HUE047808T2 (ru)
IL (2) IL247328B (ru)
LT (1) LT3122378T (ru)
MX (1) MX377794B (ru)
PL (1) PL3122378T3 (ru)
PT (1) PT3122378T (ru)
RS (1) RS59971B1 (ru)
SG (1) SG11201606887WA (ru)
SI (1) SI3122378T1 (ru)
SM (1) SMT202000085T1 (ru)
WO (2) WO2015144653A1 (ru)
ZA (1) ZA201605818B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201400210RA (en) * 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
CA3023968A1 (en) 2016-05-16 2017-11-23 Infectious Disease Research Institute Formulation containing tlr agonist and methods of use
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
CN109526985B (zh) * 2018-11-19 2021-03-12 黑龙江省农垦科学院 土地类芽胞杆菌蛋白EsxA作为水稻稻瘟病生物防治剂的应用
EP3777884A1 (en) * 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
EP4038091A1 (en) 2019-10-02 2022-08-10 Janssen Vaccines & Prevention B.V. Staphylococcus peptides and methods of use
CN118480136B (zh) * 2024-06-19 2025-01-14 南京澄实生物医药科技有限公司 一种预防和治疗金黄色葡萄球菌感染的免疫原性组合物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
ATE67769T1 (de) 1983-01-25 1991-10-15 Ciba Geigy Ag Neue peptidderivate.
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
HU222250B1 (hu) 1991-03-01 2003-05-28 Minnesota Mining And Manufacturing Company 1- és 2-helyzetben szubsztituált 1H-imidazo[4,5-c]kinolin-4-amin-származékok előállításában alkalmazható intermedierek
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
DK0708772T3 (da) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (ru) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины
PT1005368E (pt) 1997-03-10 2009-11-19 Coley Pharm Gmbh Utilização de ácidos nucleicos contendo dinucleótidos cpg não metilados em combinação com alúmen como adjuvante
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
BR9811262A (pt) * 1997-04-01 2000-10-17 Ribi Immunochem Research Inc Composições auxiliares imunológicas aquosas de lipìdio de monofosforila a.
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
JP4413435B2 (ja) 1998-10-22 2010-02-10 陽介 内藤 シャワーヘッド
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
KR100865706B1 (ko) 2000-09-26 2008-10-28 이데라 파마슈티칼즈, 인코포레이티드 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6743920B2 (en) 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
PT1742659E (pt) 2004-04-05 2013-06-03 Pah Usa 15 Llc Emulsões de óleo em água microfluidizadas e composições de vacinas
WO2007001423A2 (en) * 2004-10-21 2007-01-04 Wyeth Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
MX2008015814A (es) 2006-06-12 2009-01-12 Nabi Biopharmaceuticals Uso de alfa-toxina para tratar y prevenir infecciones por staphylococcus.
AU2007269557B2 (en) 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
CA2664619C (en) 2006-10-12 2012-12-11 Glaxosmithkline Biologicals S.A. Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent
US20090007256A1 (en) 2007-06-28 2009-01-01 Microsoft Corporation Using a trusted entity to drive security decisions
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
HRP20150892T1 (hr) 2008-03-03 2015-09-25 Novartis Ag Spojevi i sastavi kao modulatori tlr-aktivnosti
SI2276486T1 (sl) 2008-03-24 2014-01-31 4Sc Discovery Gmbh Novi substituirani imidazokinolini
PL2313111T3 (pl) 2008-08-01 2014-08-29 Ventirx Pharmaceuticals Inc Preparaty agonistów receptora Toll-podobnego i ich zastosowanie
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
SI3281947T1 (sl) * 2009-04-03 2020-07-31 The University Of Chicago Sestave in metode v zvezi z variantami proteina A (SPA)
WO2011127032A1 (en) * 2010-04-05 2011-10-13 University Of Chicago Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
CN109248313B (zh) * 2009-04-14 2023-01-17 葛兰素史密丝克莱恩生物有限公司 用于免疫接种以抵御金黄色葡萄球菌的组合物
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
WO2012034067A1 (en) * 2010-09-09 2012-03-15 The University Of Chicago Methods and compositions involving protective staphylococcal antigens
SG11201400210RA (en) 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
CN104023744A (zh) 2011-12-23 2014-09-03 诺华股份有限公司 用于针对金黄色葡萄球菌免疫的稳定组合物
LT2822947T (lt) 2012-03-07 2016-10-10 Glaxosmithkline Biologicals Sa Tlr7 agonisto arginino druskos
CA2866406A1 (en) 2012-03-08 2013-09-12 Novartis Ag Adjuvanted formulations of booster vaccines
CN104684570A (zh) 2012-08-31 2015-06-03 诺华股份有限公司 用于免疫抵抗金黄色葡萄球菌的稳定化的蛋白质
US20150202277A1 (en) 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
WO2014033191A1 (en) 2012-08-31 2014-03-06 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
PT2890394T (pt) 2012-08-31 2019-07-15 Glaxosmithkline Biologicals Sa Proteínas estabilizadas para imunização contra staphylococcus aureus
CN103694322B (zh) * 2013-12-09 2016-08-17 成都欧林生物科技股份有限公司 金黄色葡萄球菌SpA5突变体及其制备方法和应用
CN103645318B (zh) * 2013-12-09 2016-11-02 成都欧林生物科技股份有限公司 金黄色葡萄球菌SpA5突变体抗原特异性IgG抗体检测方法和检测试剂盒

Also Published As

Publication number Publication date
ES2769647T3 (es) 2020-06-26
JP2021035950A (ja) 2021-03-04
CN112521464A (zh) 2021-03-19
HRP20200217T1 (hr) 2020-05-15
KR20160132109A (ko) 2016-11-16
JP6894237B2 (ja) 2021-06-30
HUE047808T2 (hu) 2020-05-28
AU2015238512B2 (en) 2018-02-01
CA2942450A1 (en) 2015-10-01
US20180064800A9 (en) 2018-03-08
EP3122378A1 (en) 2017-02-01
LT3122378T (lt) 2020-02-10
US20170143816A1 (en) 2017-05-25
SG11201606887WA (en) 2016-09-29
EP3122378B1 (en) 2019-12-11
MX377794B (es) 2025-03-10
WO2015144655A1 (en) 2015-10-01
MX2016012538A (es) 2016-12-14
KR20190040101A (ko) 2019-04-16
BE1022857A1 (fr) 2016-09-27
WO2015144653A1 (en) 2015-10-01
JP2017511312A (ja) 2017-04-20
IL247328A0 (en) 2016-09-29
BE1022744A1 (fr) 2016-08-29
CY1122537T1 (el) 2021-01-27
KR20190110655A (ko) 2019-09-30
AU2015238512A1 (en) 2016-10-13
IL247328B (en) 2021-04-29
RS59971B1 (sr) 2020-03-31
BE1022744B1 (fr) 2016-08-29
CN106103469A (zh) 2016-11-09
SMT202000085T1 (it) 2020-03-13
ZA201605818B (en) 2022-05-25
US10328140B2 (en) 2019-06-25
KR102027429B1 (ko) 2019-10-01
IL282104A (en) 2021-05-31
DK3122378T3 (da) 2020-03-02
CN106103469B (zh) 2020-11-27
KR102297357B1 (ko) 2021-09-02
PL3122378T3 (pl) 2020-06-01
PT3122378T (pt) 2020-03-04
EA037818B1 (ru) 2021-05-25
BR112016022011A2 (pt) 2017-10-24
EP3639850A1 (en) 2020-04-22
SI3122378T1 (sl) 2020-03-31

Similar Documents

Publication Publication Date Title
EA201691502A1 (ru) Мутантные стафилококковые антигены
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
PH12016502518A1 (en) Monoclonal antibodies against her2 epitope and methods of use thereof
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
MX2019009660A (es) Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201600473A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Tau(PS422) И СПОСОБЫ ПРИМЕНЕНИЯ
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
PH12016501366A1 (en) Novel anti-baff antibodies
PH12016501435A1 (en) Anti-jagged1 antibodies and methods of use
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
BR112017015880A2 (pt) anticorpos, usos e métodos
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
NZ710744A (en) Methods for increasing immunoglobulin a levels
EA201692554A1 (ru) Менингококковые вакцины
MX2015010110A (es) Diseño de inmunogenos a base de linaje de celulas b con animales humanizados.
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.
EP3231441A4 (en) Novel protein structure produced by effective antibody used for immunization
MA39355A1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
NZ629420A (en) Sheep nematode vaccine
EA201992003A1 (ru) Применение антител к ctla-4 с повышенной adcc для усиления иммунного ответа на вакцину